z-logo
Premium
Quasi‐Continuous Wave Near‐Infrared Excitation of Upconversion Nanoparticles for Optogenetic Manipulation of C. elegans
Author(s) -
Bansal Akshaya,
Liu Haichun,
Jayakumar Muthu Kumara Gnanasammandhan,
AnderssonEngels Stefan,
Zhang Yong
Publication year - 2016
Publication title -
small
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.785
H-Index - 236
eISSN - 1613-6829
pISSN - 1613-6810
DOI - 10.1002/smll.201503792
Subject(s) - optogenetics , photon upconversion , excitation , materials science , near infrared spectroscopy , optoelectronics , phototoxicity , continuous wave , infrared , overheating (electricity) , nanotechnology , nanoparticle , laser , optics , chemistry , physics , neuroscience , luminescence , biochemistry , quantum mechanics , in vitro , biology
Optogenetics is an emerging powerful tool to investigate workings of the nervous system. However, the use of low tissue penetrating visible light limits its therapeutic potential. Employing deep penetrating near‐infrared (NIR) light for optogenetics would be beneficial but it cannot be used directly. This issue can be tackled with upconversion nanoparticles (UCNs) acting as nanotransducers emitting at shorter wavelengths extending to the UV range upon NIR light excitation. Although attractive, implementation of such NIR‐optogenetics is hindered by the low UCN emission intensity that necessitates high NIR excitation intensities, resulting in overheating issues. A novel quasi‐continuous wave (quasi‐CW) excitation approach is developed that significantly enhances multiphoton emissions from UCNs, and for the first time NIR light‐triggered optogenetic manipulations are implemented in vitro and in C. elegans . The approach developed here enables the activation of channelrhodopsin‐2 with a significantly lower excitation power and UCN concentration along with negligible phototoxicity as seen with CW excitation, paving the way for therapeutic optogenetics.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here